About the special issue
Genitourinary tumors encompass a broad range of cancer types within the urinary system and male reproductive system and there are a plethora of novel investigational drugs under current clinical development for future treatments. Candidate drugs can range from Von Hippel–Lindau inhibitors, antibody-drug conjugates, anti-angiogenesis tyrosine kinase inhibitors, immune checkpoint inhibitors, and mTOR inhibitors, with each presenting important differences and considerations for individual tumors and when used in combination therapies.
In this special issue Expert Opinion on Investigational Drugs has teamed up with key opinion leaders in the field:
• Dr Alessandro Rizzo – IRCCS Istituto Tumori Giovanni Paolo II-Bari, SSD Oncologia ‘Don Tonino Bello’, Italy
• Dr Francesco Massari – IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
• Dr Veronica Mollica – IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
This issue aims to cover recent progress of investigational drugs and the implications on the future clinical development across all types of genitourinary cancers, in urinary systems of both men and women and the reproductive organs in men, including but not limited to:
• Adrenal cancers
• Bladder cancers
• Kidney cancers
• Penile cancers
• Prostate cancers
• Testicular cancers
The issue welcomes authors to submit relevant interviews, editorials, reviews, drug evaluations, meta-analyses, systematic reviews, and original research. If you are interested in contributing or would like to learn more, then please reach out to the Commissioning Editor, Ryan Gilroy , who will be happy to assist.